Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793 is registered in ClinicalTrials.gov with A2 Biotherapeutics Inc. as lead sponsor.

NCT NCT06682793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06682793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Lead sponsor
A2 Biotherapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 22, 2025
Completion date
March 31, 2030
Enrollment
240 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, colon cancer, colorectal adenocarcinoma, colorectal cancer, crc, head and neck squamous cell cancer, hnscc, kidney cancer, lung cancer, non-small cell lung, nsclc (non-small cell lung cancer), rcc, rectal cancer, renal cell carcinoma, solid tumor, adult, tnbc, triple negative breast cancer